LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Search

Pliant Therapeutics Inc

Затворен

1.17

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.1400000000000001

Максимум

1.18

Ключови измерители

By Trading Economics

Приходи

2.7M

-24M

EPS

-0.354

Служители

49

EBITDA

-5.3M

-28M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+128.21% upside

Дивиденти

By Dow Jones

Следващи печалби

7.05.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-1.2M

80M

Предишно отваряне

1.17

Предишно затваряне

1.17

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.03.2026 г., 17:33 ч. UTC

Значими събития в новините

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27.03.2026 г., 17:00 ч. UTC

Значими събития в новините

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27.03.2026 г., 16:03 ч. UTC

Значими събития в новините

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29.03.2026 г., 23:47 ч. UTC

Пазарно говорене
Значими събития в новините

Gold Falls Amid Rising Inflation Fears -- Market Talk

29.03.2026 г., 23:46 ч. UTC

Пазарно говорене
Значими събития в новините

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29.03.2026 г., 23:35 ч. UTC

Пазарно говорене
Значими събития в новините

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29.03.2026 г., 23:23 ч. UTC

Пазарно говорене

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29.03.2026 г., 22:34 ч. UTC

Пазарно говорене

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29.03.2026 г., 22:09 ч. UTC

Пазарно говорене

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29.03.2026 г., 21:06 ч. UTC

Пазарно говорене
Значими събития в новините

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29.03.2026 г., 21:03 ч. UTC

Пазарно говорене

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29.03.2026 г., 21:01 ч. UTC

Пазарно говорене
Значими събития в новините

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29.03.2026 г., 09:30 ч. UTC

Придобивния, сливания и поглъщания

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28.03.2026 г., 08:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 19:16 ч. UTC

Пазарно говорене
Значими събития в новините

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27.03.2026 г., 19:07 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27.03.2026 г., 19:04 ч. UTC

Пазарно говорене

Gold Rises But Can't Finish the Week Positive -- Market Talk

27.03.2026 г., 19:03 ч. UTC

Пазарно говорене
Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 19:02 ч. UTC

Пазарно говорене
Значими събития в новините

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27.03.2026 г., 18:12 ч. UTC

Пазарно говорене

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27.03.2026 г., 17:36 ч. UTC

Значими събития в новините

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27.03.2026 г., 17:34 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27.03.2026 г., 17:29 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27.03.2026 г., 16:38 ч. UTC

Пазарно говорене

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27.03.2026 г., 16:32 ч. UTC

Пазарно говорене
Значими събития в новините

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27.03.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 15:43 ч. UTC

Пазарно говорене
Значими събития в новините

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27.03.2026 г., 15:25 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 15:25 ч. UTC

Пазарно говорене

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

128.21% нагоре

12-месечна прогноза

Среден 2.67 USD  128.21%

Висок 3 USD

Нисък 2 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

2

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
help-icon Live chat